Our vision at Alzheon
We strive to change the standard of care.
Passion
We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.
Innovation
We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently move towards new therapeutic solutions with substantially lower development risk.
Patients
We are committed to improving the lives of patients, their families and caregivers.
Impact
We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.
For patients and caregivers
Study has completed with long term extension (LTE) ongoing.
Click here for more information at ClinicalTrials.gov
Single arm Phase 2 biomarker study in APOE4 carriers completed.
Click here for more information.
Valiltramiprosate/ALZ-801 is an investigational product in clinical development, and its use has not been approved by the FDA or EMA.